Introduction
There are several provocative links between stem cells and the induction of specific immune tolerance. More than one stem cell type has been associated with immune tolerance induction, including embryonic, hematopoietic and mesenchymal stem cells [3] [4] [5] [6] [7] .
These stem cells have been successfully employed for tolerance induction in a variety of rodent and large animal studies. A previous report 8 , suggests that MSC are not only able to evade allogeneic immune system, but they can also suppress immune responses directed against third party cells, even inducing tolerance towards other tissues of the same origin when transplanted following intravenous infusion of MSC. This and other studies have further demonstrated that MSC inhibit T cell activation ex vivo [8] [9] [10] [11] . A recent case report has suggested that systemic infusion of haploidentical mesenchymal stem cells suppressed a grade 4 graft-versus-host-disease (GVHD) in a bone marrow transplanted 9-year-old child 12 . Nevertheless, the underlying mechanism for this tolerizing phenomenon, including the involved target cells, is not yet known.
Tolerance induction in the periphery is believed to be critical for the prevention of autoimmunity and maintenance of immune homeostasis. Central tolerance has been classically ascribed to clonal deletion of self-reactive T cells in the thymus upon interaction with self-antigens. However, central tolerance is incomplete, since not all self-antigens gain access to the thymus and several self-reactive lymphocytes escape central deletion.
Over the past several years there is growing evidence supporting this notion, revealing
For personal use only. on . by guest www.bloodjournal.org From 4 subpopulations of cells representing different arms of the immune system, as potential regulators of the immune system. These specific groups include T cell subtypes (such as CD4+CD25+ T cells), as well as unique fraction of dendritic cells (DC) described as semimature DC, all of whom were shown to possess immune modulating properties. Therefore, 'sentinels' in the periphery of the body are essential to maintain tolerance as well as immunity. These tolerogenic effectors, while constitutively active in autoimmunity prevention, may play a pivot roll in maternal-fetal non-rejection, as well as in immune evasion of tumors and metastases.
Taken together, these studies on MSC with their potential immunoregulatory activities create a compelling case for further pursuing stem cells as cellular tolerogens in the periphery. Given the uniqueness and potential importance of this observation, in this study we explore the mechanism underlying the immunoregulatory properties of human MSC (hMSC) and their ability to inhibit T cell activation. Our data have uncovered a unique immunoregulatory mechanism wherein human mesenchymal stem cells (hMSC) induce regulatory antigen-presenting cells (APC) that in turn inhibit T cell activation. 
Results
Several previous studies [8] [9] [10] [11] have demonstrated that MSC have immunoregulatory effects on T cells. These studies create a compelling case for further pursuing stem cells as cellular tolerogens. Given the uniqueness and potential importance of this observation, in this study we explore the mechanism underlying the immunoregulatory properties of human MSC (hMSC) and their ability to inhibit T cell activation. To this end, hMSC were derived from discarded bone tissues obtained from patients undergoing total hip replacement. The hMSC were separated from other bone-marrow residing cells by plastic adherence, and then were grown under tissue culture conditions as previously described 1, 13 , and tested for their ability to inhibit T cell activation, as measured by cytokine secretion and T cell proliferation.
As described previously (Fig. 1A) and was independent of the concentration of stimulus (PHA; data not shown) or SEB ( Fig   1B) . hMSC inhibitory activity was retained following γ-irradiation, but not after paraformaldehyde-fixation (data not shown) as previously observed 8 . As was previously reported 10 , there is cell:cell contact dependence of hMSC-mediated inhibition based on the absence of inhibition when hMSC were replaced with their conditioned media (data not shown), or when PBMC and hMSC were on opposite sides of a transwell membrane (Fig.   1C ). Interestingly, IFN-γ secretion as well as proliferation could be partially restored in hMSC-containing cultures by adding either LPS or anti-CD40 mAb (Fig. 1D) . Given that triggering APC such as monocytes with either LPS or anti-CD40 mAb is known to promote These experiments employed monocytes as APC, showing that they can be conditioned by hMSC to inhibit T cells. Given that dendritic cells (DC) are prototypical professional APC, we questioned whether DC can be similarly conditioned by hMSC. To this end, we repeated the experiments described above, using monocyte-derived DC in place of monocytes. Peripheral monocytes were cultured with GM-CSF and IL-4 for 7 days according to a standard protocol, and their subsequent ability to inhibit T cell activation in the presence of hMSC, was tested. Titrating the number of DC added to the hMSC cocultures inhibited IFN-γ secretion and T cell proliferation in a dose-dependent manner.
Thus, DC parallel monocytes in their effects on T cell activation in this hMSC-induced immunoregulatory system. Furthermore, we tested the possibility that this hMSC-elicited inhibitory property of DC was somehow dependent upon a DC maturation state at the time of hMSC contact. DC that had been grown with GM-CSF and IL-4 for 7 days were then For personal use only. on April 10, 2017. by guest www.bloodjournal.org From exposed to LPS for one more day, prior to washing and adding them to hMSC co-cultures.
Inhibition of T cell activation in these co-cultures was significantly reduced as compared to DC that had not been treated with LPS (data not shown). This LPS priming, reversed the inhibitory phenotype, presumably by overriding hMSC-mediated block of DC maturation.
We next tested the hypothesis that hMSC influence APC maturation, somehow locking them into an immature or semi-mature phenotype that correlates with T cell inhibition 14, 15 . Therefore, we molecularly profiled hMSC-conditioned APC, comparing them to nonconditioned APC as controls, looking at both secreted cytokines for which APCs are the main producers using ELISA, and surface molecules by immunofluorescence and flow cytometry.
To this end, monocytes were co-cultured with CD4 + T cells in the presence or absence of hMSC and cytokine secretion was determined in the conditioned media. While unactivated monocytes secreted low levels of IL-12, TNF-α and IL-1β secretion, these levels were substantially increased upon SEB stimulation. In contrast, stimulation in the presence of hMSC resulted in significantly lower levels of SEB-induced IL-12 and TNF-α; however, there was no effect on IL-1β secretion (Fig 3A) . Similar results were obtained when DC were used instead of monocytes (Fig. 3B) , except that low levels of IL-1β were detected exclusively when hMSC were present (Fig. 3B, lower panel) .
We further looked for the expression of the surface molecule on CD14 + (monocytes; and DC expressed relatively low levels of CD86 and HLA-DR, which were increased upon SEB stimulation. HLA-DR upregulation in monocytes was significantly reduced by hMSC (Fig 3C, upper panel, and to a lesser degree in DC (Fig 3D, upper panel) . On the other hand, the level of CD86 expression on monocytes and DC was not significantly affected by the presence of hMSC (Fig 3C and D, lower panels) . These findings seem to represent a unique developmental stage for APC appearing to be similar to that of immature APC, yet differing from immature APC in their IL-1β and CD86 expression. Thus, this data suggest that hMSC partially block APC maturation leading to an aberrant APC phenotype, with dissociation of otherwise clustered molecular markers. These APC lack T cell activating capacity and possibly produce some inhibitory molecule(s) that can trigger T cell inhibitory events. . We therefore tested whether these cytokines play a role in hMSC-mediated inhibition. First, the levels of TGF-β were determined in the conditioned media of either PBMCs or monocytes that were cocultured with CD4 + T cells, both in the presence or absence of hMSC or hMSC cultured alone (Fig. 4A) . TGF-β was detected in conditioned media of both hMSC and immune cells. The level of TGF-β in the co-cultures was the expected additive amount of the two cell types, indicating that the interaction of immune cells:hMSC does not result in increased TGF-β secretion (Fig. 4A) . Furthermore, the addition of neutralizing Abs (specific for human TGF-β 1-2 ) had no effect on the inhibitory activity of hMSC as determined by IFN-γ (Fig. 4B) . These data support the notion that TGF-β does not play a major role in hMSC-mediated inhibitory activity. Next, the possible role of IL-10 in mediating hMSC-induced immunomodulation was examined. Interestingly, while PBMC, monocytes, or both CD4 + T cells and monocytes (but not DC; data not shown) secreted relatively low levels of IL-10, we detected up to a 10-fold increase in the concentrations of IL-10 in conditioned media of these cells when co-cultured with hMSC, regardless of the presence of SEB. Given that no IL-10 was detected in conditioned media of hMSC cultures (Fig. 4C, right panel) , these data suggest that co-culturing hMSC with these immune cells induced the secretion of relatively high levels of IL-10 (Fig. 4C) . To test whether IL-10 11 contributes to hMSC-derived T cell inhibition once APC are added to the system, we determined if addition of neutralizing anti-IL-10 receptor Abs abrogate inhibition and restore T cell responses. Although addition of anti-IL-10 receptor Abs increased IFN-γ and TNF-α secretion as well as the proliferative response, these responses were still lower as compared to control cultures. Thus, the inhibitory effect of hMSC was only partially reverted by blocking IL-10 activity (Fig. 4D) .
Notwithstanding that this hMSC-induced IL-10 is not inhibitory on its own (given that hMSC on their own activate T cells, despite the presence of IL-10 in the conditioned media of this co-culture (data not shown) and the moderate effect of the neutralizing anti-IL10 receptor Ab), there remains the possibility that IL-10 works in concert with other immunoinhibitory factor(s) derived from hMSC-conditioned APC.
For
Discussion
Previous studies have suggested that MSC inhibit T cell activation and can induce immune tolerance. However, the precise mechanism underlying this phenomenon is still unclear.
While one study suggested that hMSC interfere with T cell:APC contact 10 , a second study suggested that the hMSC themselves act as veto cells 17 . The present data offer a different view, namely, an indirect inhibitory effect of hMSC mediated by the APC. Accordingly, the primary effect of hMSC is to convert APC into what is effectively a "deletional APC" with active immunoregulatory properties, as opposed to simply being activation incompetent.
The critical observation here is that hMSC can efficiently activate highly purified T cells (possibly due to expression of HLA-DR 17 and CD80 10 by the hMSC) and surprisingly, addition of APC attenuates this activation event. Obviously, our findings differ from those described by Krampera et.al, 10 . Using mouse MSC, Krampera et al., 10 have demonstrated contact-dependent inhibition of T cell activation. However, the authors of that study have concluded that MSC hinder T cell from the contact with APC in a noncognate fashion, and that the presence of APC is not required for MSC to inhibit. At this stage, it is not clear why our data departs from the previous report (e.g. perhaps a species human versus mouse difference), but in any case, our results, using human cells, support the hypothesis proposed here, namely that in the presence of hMSC, APC are transformed into regulatory APC.
There is a large and growing literature bearing upon the regulatory APC concept (reviewed in 14, 18 ). Over the past several years, the limited conception of APC, and DC in particular, as positive regulators (i.e., as natural "adjuvants" that promote immune responses to foreign antigens) has been expanded to encompass the notion of APC as negative regulators, with the recognition that APC involved in immune induction are likely to also be involved in the induction of tolerance to self-antigens 19 . Two general mechanisms have been proposed by which DC might maintain peripheral tolerance. The first is that a subtype of specialized regulatory DC maintains peripheral tolerance. The second is that all DC have the ability to induce tolerance, with the capacity to induce tolerance or immunity dependent on the maturation or activation state of the DC 14, 15 .
According to this mechanism the functional activities of DC are mainly dependent on their
For personal use only. on April 10, 2017. by guest www.bloodjournal.org From state of activation and maturation; that is, terminally-differentiated, mature DC can efficiently induce the development of T effector cells, whereas "immature" or "semi-mature" DC maintain peripheral tolerance. Full APC maturation can be triggered by Toll-like receptors (TLRs; e.g. with LPS, CpG oligodexynucleotides) or by ligation of CD40 by CD40L. Given our observation that LPS or anti-CD40 mAb can partially override hMSCdriven T cell inhibition (Fig. 1D) 
